“Tralokinumab Improves Clinically Relevant Outcome Measures: A Post Hoc Analysis of ECZTRA 3, A Randomized Clinical Trial in Patients With Moderate-To-Severe Atopic Dermatitis”. SKIN The Journal of Cutaneous Medicine, vol. 4, no. 6, Oct. 2020, p. s100, https://doi.org/10.25251/skin.4.supp.100.